Matchpoint Therapeutics
PrivateLast Round
Series B
Oct 7, 2026
Total Funding Raised
$250M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Matchpoint Therapeutics is a biotechnology company that develops precision small molecule medicines leveraging covalency to treat immune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Matchpoint Therapeutics Comparables
Compare Matchpoint Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Totus Medicines | 88% | |
| Dunad Therapeutics | 85% | |
| BridGene Biosciences | 85% |
Matchpoint Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 7, 2026 | ||||
| Corporate Funding | Jul 24, 2025 | ||||
| Series A | Oct 14, 2022 | ||||
| Seed | Nov 30, 2021 |
Matchpoint Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Access Industries | Seed |
| Vertex Ventures HC | Series A |
| Digitalis Ventures | Series B, Series A |
| BB Biotech | Series B |
| Norwest Venture Partners | Series B |
| Alexandria Venture Investments | Series A |
| BOLD Capital Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 7, 2026
$150M round led by Norwest Venture Partners and Nextech Invest.
- Jul 24, 2026
Monthly visitors increased 38% MoM.
Recent news
Latest coverage and updates
- hiresOct 14, 2026
Matchpoint Therapeutics, Inc appoints John O'Malley, M.D., Ph.D., as Chief Medical Officer to expand its leadership team in Massachusetts on Oct 14th '26.
- hiresOct 14, 2026
Matchpoint Therapeutics, Inc announces the appointment of John O'Malley, M.D., Ph.D., as Chief Medical Officer in Massachusetts on Oct 14th '26, following its recent $150M Series B financing as it advances its lead program into clinical development.
- licenses_technologyOct 13, 2026
Under a collaboration signed in Jul '25, Matchpoint Therapeutics, Inc grants Novartis Pharmaceuticals Corporation an exclusive option to license an oral programme targeting an inflammatory disease pathway.
- hiresOct 7, 2026
On Oct 10th '26, Matchpoint Therapeutics, Inc announces Kanishka Pothula, Nextech's managing partner, joins its board alongside Norwest Principal Brian Matesic as MPT-062 prepares for clinical development in 2027.
- is_developingOct 7, 2026
Matchpoint Therapeutics, Inc expects to start clinical development of oral T cell modulator MPT-062 for autoimmune and inflammatory conditions in Massachusetts in 2027.
Matchpoint Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Matchpoint Therapeutics's valuation, stock price, and market status.
Is Matchpoint Therapeutics a public or private company?
Matchpoint Therapeutics is a private company.
What is the current stock price of Matchpoint Therapeutics?
Matchpoint Therapeutics is a private company, so its shares have no public market price. Caplight tracks Matchpoint Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Matchpoint Therapeutics worth (valuation)?
Valuation information for Matchpoint Therapeutics is not publicly available.
Can I buy Matchpoint Therapeutics stock?
Matchpoint Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Matchpoint Therapeutics's last funding round?
Matchpoint Therapeutics's most recent funding round was Series B on October 7, 2026.
Who are the main investors in Matchpoint Therapeutics?
Key investors in Matchpoint Therapeutics include Access Industries, Norwest Venture Partners, Sanofi Ventures, Atlas Venture, Nextech Invest.
Will Matchpoint Therapeutics IPO soon?
No public IPO plans have been announced for Matchpoint Therapeutics.
How can I track Matchpoint Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Matchpoint Therapeutics's shares on secondary markets.